Lumizyme® (alglucosidase alfa) (Intravenous)

Last Review Date: January 1, 2020
Number: MG.MM.PH.92

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated, GHI HMO Select, ConnectiCare, Inc., ConnectiCare Insurance Company, Inc. ConnectiCare Benefits, Inc., and ConnectiCare of Massachusetts, Inc. related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

LENGTH OF AUTHORIZATION

Coverage will be provided for 12 months and may be renewed.

DOSSING LIMITS

Max Units (per dose and over time) [Medical Benefit]:

- 230 billable units every 14 days

Guideline

I. INITIAL APPROVAL CRITERIA

Coverage is provided in the following conditions:

Pompe disease (Acid alpha-glucosidase (GAA) deficiency) †

- Diagnosis has been confirmed by one of the following:
  - Deficiency of acid alpha-glucosidase enzyme activity; OR
  - Detection of pathogenic variants in the GAA gene by molecular genetic testing; AND
- Documented baseline values for one or more of the following:
  - Infantile-onset disease: muscle weakness, motor function, respiratory function, cardiac involvement, percent predicted forced vital capacity (FVC), and/or 6 minute walk test (6MWT); OR
II. **RENEWAL CRITERIA**

Coverage can be renewed based upon the following criteria:

- Patient continues to meet the criteria above; **AND**

- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe allergic and anaphylactic reactions, severe cutaneous and systemic immune-mediated reactions, acute cardiorespiratory failure, cardiac arrhythmia and sudden cardiac death during general anesthesia, etc.; **AND**

- No evidence that patient has developed IgG antibodies to alglucosidase alfa at a sustained titer level of ≥ 12,800; **AND**

- Patient has demonstrated a beneficial response to therapy compared to pretreatment baseline in one or more of the following:

  - Infantine-onset disease: stabilization or improvement in muscle weakness, motor function, respiratory function, cardiac involvement, FVC, and/or 6MWT

  - Late-onset (non-infantine) disease: stabilization or improvement in FVC and/or 6MWT

**Limitations/Exclusions**

Lumizyme is not considered medically necessary for indications other than those listed above due to insufficient evidence of therapeutic value.

**Applicable Procedure Codes**

<table>
<thead>
<tr>
<th>J0221</th>
<th>Injection, alglucosidase alfa, (Lumizyme), 10 mg; 1 billable unit = 10 mg</th>
</tr>
</thead>
</table>

Note: J0220

| Injection, alglucosidase alfa, 10 mg, not otherwise specified – applicable to Myokymia (Genzyme Corporation) - NDC inactive as of 3/24/16 |

**Applicable NDCs**

| 58468-0160-xx | Lumizyme 50 mg single-use vial for injection |

**Applicable Diagnosis Codes**

| E74.02 | Pompe disease |

**Revision History**

N/A
References


